PMID- 8955921
OWN - NLM
STAT- MEDLINE
DCOM- 19970401
LR  - 20190614
IS  - 0006-8993 (Print)
IS  - 0006-8993 (Linking)
VI  - 739
IP  - 1-2
DP  - 1996 Nov 11
TI  - Involvement of the nucleus accumbens-ventral pallidal pathway in postictal 
      behavior induced by a hippocampal afterdischarge in rats.
PG  - 26-35
AB  - The hypothesis that postictal motor behaviors induced by a hippocampal 
      afterdischarge (AD) are mediated by a pathway through the nucleus accumbens (NAC) 
      and ventral pallidum (VP) was evaluated in freely moving rats. Tetanic 
      stimulation of the hippocampal CA1 evoked an AD of 15-30 s and an increase in 
      number of wet-dog shakes, face washes, rearings and locomotor activity. Bilateral 
      injection of haloperidol (5 micrograms/side) or the selective dopamine D2 
      receptor antagonist, (+/-)-sulpiride (200 ng/side) before the hippocampal AD, 
      into the NAC selectively reduced rearings and locomotor activity, but not the 
      number of wet-dog shakes and face washes. Injection of R(+)-SCH-23390 (1 
      microgram/side), a D1 receptor antagonist, or rimcazole (0.4 mg/side), a sigma 
      opioid receptor antagonist, into the NAC did not significantly alter postictal 
      behaviors. Bilateral injection of muscimol (1 ng/side), a gamma-aminobutyric acid 
      (GABAA) receptor agonist, into the VP before the AD significantly blocked all 
      postictal behaviors. It is concluded that postictal locomotor activity induced by 
      a hippocampal AD is mediated by activation of dopamine D2 receptors in the NAC 
      and a pathway through the VP.
FAU - Ma, J
AU  - Ma J
AD  - Department of Physiology, University Hospital, University of Western Ontario, 
      London, Canada.
FAU - Brudzynski, S M
AU  - Brudzynski SM
FAU - Leung, L W
AU  - Leung LW
LA  - eng
GR  - NS-25383/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Brain Res
JT  - Brain research
JID - 0045503
RN  - 0 (Dopamine Antagonists)
RN  - 0 (Dopamine D2 Receptor Antagonists)
RN  - 0 (GABA Agonists)
RN  - 0 (Receptors, Dopamine D1)
RN  - 2763-96-4 (Muscimol)
RN  - J6292F8L3D (Haloperidol)
SB  - IM
MH  - Animals
MH  - Behavior, Animal/drug effects/*physiology
MH  - Dopamine Antagonists/pharmacology
MH  - Dopamine D2 Receptor Antagonists
MH  - Electric Stimulation
MH  - Epilepsy, Temporal Lobe/*physiopathology
MH  - Evoked Potentials, Motor/drug effects/*physiology
MH  - GABA Agonists/pharmacology
MH  - Globus Pallidus/drug effects/*physiology
MH  - Haloperidol/pharmacology
MH  - Hippocampus/drug effects/*physiology
MH  - Male
MH  - Muscimol/pharmacology
MH  - Neural Pathways/drug effects/physiology
MH  - Nucleus Accumbens/drug effects/*physiology
MH  - Rats
MH  - Receptors, Dopamine D1/antagonists & inhibitors
EDAT- 1996/11/11 00:00
MHDA- 1996/11/11 00:01
CRDT- 1996/11/11 00:00
PHST- 1996/11/11 00:00 [pubmed]
PHST- 1996/11/11 00:01 [medline]
PHST- 1996/11/11 00:00 [entrez]
AID - S0006-8993(96)00793-7 [pii]
AID - 10.1016/s0006-8993(96)00793-7 [doi]
PST - ppublish
SO  - Brain Res. 1996 Nov 11;739(1-2):26-35. doi: 10.1016/s0006-8993(96)00793-7.